Status:
COMPLETED
A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses ...
Eligibility Criteria
Inclusion
- Male and female participants who are overtly healthy as determined by medical evaluation
- Have a body mass index with the range of 18 and less than or equal to (≤) 32 kilograms per square meter (kg/m²)
- Male or female participants of nonchildbearing potential
Exclusion
- Have a family history, defined as a parent or first-degree relative, of genetic neurodegenerative disorders
- Have allergies to diphenhydramine, epinephrine, or methylprednisolone
- Have serious or unstable medical conditions,
- History of skin wounding within 14 days of screening or current skin infection
- Are unwilling to stop alcohol consumption 48 hours prior to each dosing
- Have active or latent tuberculosis
- Participants in the cohorts undergoing lumbar puncture have an allergy to local anesthetics
Key Trial Info
Start Date :
August 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2025
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT06007638
Start Date
August 23 2023
End Date
September 20 2025
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICON Early Phase Services, LLC
Groningen, Netherlands, 9728 NZ